GPT and fatty liver disease: In this case, the marked reduction in CRP (17.3 → 2.7 mg/L), improved insulin resistance (HOMA-IR: 5.74 → 4.08), and resolution of hepatic steatosis (ALT: 58 → 48 U/L; AST: 48 → 26 U/L) corroborate these mechanistic pathways.